|
| A) | These proteins can affect pharmacokinetics. | ||
| B) | Breast cancer resistance protein moves drugs into the liver. | ||
| C) | Most available data are related to organic anion transporting polypeptides. | ||
| D) | It is rare for medications to impact P-gp and CYP450. |
| A) | BCRP | ||
| B) | MATEs | ||
| C) | OATPs | ||
| D) | P-gp |
| A) | Apixaban and dabigatran | ||
| B) | Edoxaban and rivaroxaban | ||
| C) | Apixaban and rivaroxaban | ||
| D) | Edoxaban and dabigatran |
| A) | Nafcillin | ||
| B) | Oxcarbazepine | ||
| C) | Rifabutin | ||
| D) | Voriconazole |
| A) | Amiodarone | ||
| B) | Diltiazem | ||
| C) | Erythromycin | ||
| D) | Phenytoin |
| A) | Rifampin | ||
| B) | Ritonavir | ||
| C) | Ranolazine | ||
| D) | Famotidine |
| A) | Itraconazole | ||
| B) | Levofloxacin | ||
| C) | Phenytoin | ||
| D) | Famotidine |
| A) | All DOACs should be held during treatment with nirmatrelvir/ritonavir. | ||
| B) | Nirmatrelvir/ritonavir may be a concern with DOACs because it inhibits CYP3A4 and P-gp. | ||
| C) | DOAC doses should generally be increased during treatment with nirmatrelvir/ritonavir. | ||
| D) | Nirmatrelvir/ritonavir may be a concern with DOACs because it induces CYP1A2 and P-gp. |
| A) | Reduce the apixaban dose by 50%. | ||
| B) | Change apixaban to rivaroxaban. | ||
| C) | Change apixaban to warfarin. | ||
| D) | Continue apixaban at the standard dose. |
| A) | Continue apixaban and aspirin. | ||
| B) | Stop aspirin. | ||
| C) | Change aspirin to clopidogrel. | ||
| D) | Reduce the apixaban dose by 50%. |